NovoCure Ltd. (NVCR)
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What Makes NovoCure (NVCR) a New Buy Stock
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
NovoCure: Loading Up On Growth Catalysts
NovoCure's Q1 earnings beat and strong commercial momentum, especially with Optune Lua in NSCLC, signal renewed growth potential and investor optimism. Key catalysts ahead include the PANOVA-3 data at ASCO, PMA submissions, and possible NCCN guideline inclusion, all of which could drive adoption and revenue. International expansion, particularly in Europe and Japan, is accelerating, with robust demand and a solid cash position supporting pipeline and scaling efforts.
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
The mean of analysts' price targets for NovoCure (NVCR) points to a 105.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why NovoCure Stock Skyrocketed This Week
Shares of NovoCure (NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m.
Why NovoCure Stock Leaped 4% Higher Today
Thursday morning NovoCure (NVCR 4.28%) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index.
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.36 per share a year ago.
NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
